Intellia Therapeutics, Inc. (NTLA) Given New $28.00 Price Target at Credit Suisse Group
Intellia Therapeutics, Inc. (NASDAQ:NTLA) had its price objective upped by Credit Suisse Group from $24.00 to $28.00 in a research report sent to investors on Friday morning. The brokerage currently has an outperform rating on the stock.
A number of other equities research analysts have also recently weighed in on the stock. ValuEngine raised shares of Intellia Therapeutics from a sell rating to a hold rating in a research report on Friday, September 22nd. Jefferies Group LLC set a $42.00 price target on shares of Intellia Therapeutics and gave the company a buy rating in a research report on Tuesday, October 31st. Leerink Swann boosted their price target on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an outperform rating in a research report on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush reissued an ourperform rating and issued a $25.00 price target (down from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, Zacks Investment Research raised shares of Intellia Therapeutics from a sell rating to a hold rating in a research report on Wednesday, October 4th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $30.17.
Intellia Therapeutics (NASDAQ NTLA) traded up $0.94 during mid-day trading on Friday, hitting $21.94. 1,761,134 shares of the stock traded hands, compared to its average volume of 745,927.
Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The firm had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. During the same period last year, the company posted ($0.22) EPS. Intellia Therapeutics’s quarterly revenue was up 49.0% compared to the same quarter last year. analysts anticipate that Intellia Therapeutics will post -1.68 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/intellia-therapeutics-inc-ntla-given-new-28-00-price-target-at-credit-suisse-group/1681476.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of NTLA. SG Americas Securities LLC acquired a new position in Intellia Therapeutics in the second quarter valued at $101,000. Bank of Montreal Can increased its stake in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after purchasing an additional 7,222 shares during the period. Nationwide Fund Advisors increased its stake in Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after purchasing an additional 4,351 shares during the period. Nisa Investment Advisors LLC acquired a new position in Intellia Therapeutics in the second quarter valued at $134,000. Finally, Russell Investments Group Ltd. acquired a new position in Intellia Therapeutics in the first quarter valued at $137,000. Institutional investors own 47.77% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.